Ad
related to: pharmaceutical developer of celebrex
Search results
Results From The WOW.Com Content Network
Celecoxib, sold under the brand name Celebrex among others, is a COX-2 inhibitor and nonsteroidal anti-inflammatory drug (NSAID). [7] It is used to treat the pain and inflammation in osteoarthritis, acute pain in adults, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, painful menstruation, and juvenile rheumatoid arthritis. [7]
As Celebrex is Pfizer's fourth best-selling drug, raking in $2.9 billion in revenue in 2013 and showing stellar growth year over year of 9%, it's understandable if this court decision rattles ...
Monsanto acquired the pharmaceutical company G. D. Searle & Company in 1985. [9] In 1998, Searle and the Monsanto Pharma Sector partnered with Pfizer to develop and promote celecoxib, an anti-inflammatory drug used to treat arthritis. [10] [11] Branded as Celebrex, celecoxib was approved by the FDA in 1998. [12]
There's reason to celebrate for Celebrex. Pfizer announced today that the U.S. Patent and Trademark Office has added 18 months onto the pharmaceutical company's previous patent for the painkiller ...
[5] [6] It took less than eight years to develop and market the first COX-2 inhibitor, with Celebrex launched in December 1998 and Vioxx launched in May 1999. [7] [8] Celecoxib and other COX-2 selective inhibitors, valdecoxib, parecoxib, and mavacoxib, were discovered by a team at the Searle division of Monsanto led by John Talley.
Reportedly, there are five companies clamoring to sell cheaper, generic versions of the drug, with Mylan and Teva 3 Reasons Pfizer, Inc. Can Overcome Celebrex Patent Loss
G.D. Searle, LLC is a wholly owned subsidiary of Pfizer. [1] It is currently a trademark company and subsidiary of Pfizer, operating in more than 43 countries. It also operates as a distribution trademark for various pharmaceuticals that were developed by G. D. Searle & Company (often referred to as Searle).
Celebrex (and other brand names for celecoxib) was introduced in 1999 and rapidly became the most frequently prescribed new drug in the United States. By October 2000, its US sales exceeded 100 million prescriptions per year for $3 billion, and was still rising. Sales of Celebrex alone reached $3.1 billion in 2001.